H.C. Wainwright initiated coverage of Enveric Biosciences with a Buy rating and $10 price target. The company’s pipeline assets represent an early opportunity to invest in next-generation neuroplastogens, the analyst tells investors in a research note. The firm says Enveric is developing novel, small-molecule therapeutics as treatments for anxiety, depression, and other mental health disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENVB: